Myasthenia Gravis - Pipeline Review, H2 2016

Date: July 30, 2016
Pages: 116
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M5A35F8A463EN
Leaflet:

Download PDF Leaflet

Myasthenia Gravis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Myasthenia Gravis - Pipeline Review, H2 2016’, provides an overview of the Myasthenia Gravis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis
  • The report reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Myasthenia Gravis therapeutics and enlists all their major and minor projects
  • The report assesses Myasthenia Gravis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Myasthenia Gravis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Myasthenia Gravis Overview
Therapeutics Development
Pipeline Products for Myasthenia Gravis - Overview
Pipeline Products for Myasthenia Gravis - Comparative Analysis
Myasthenia Gravis - Therapeutics under Development by Companies
Myasthenia Gravis - Therapeutics under Investigation by Universities/Institutes
Myasthenia Gravis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Myasthenia Gravis - Products under Development by Companies
Myasthenia Gravis - Products under Investigation by Universities/Institutes
Myasthenia Gravis - Companies Involved in Therapeutics Development
Achillion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Alpha Cancer Technologies Inc.
arGEN-X BV
Biokine Therapeutics Ltd.
BioMarin Pharmaceutical Inc.
CuraVac, Inc.
GlaxoSmithKline Plc
Grifols, S.A.
HanAll Biopharma Co., Ltd.
Karus Therapeutics Limited
Millennium Pharmaceuticals Inc
Neurotune AG
Novartis AG
Pfizer Inc.
ReceptoPharm, Inc.
Regenesance BV
Shire Plc
Toleranzia AB
Myasthenia Gravis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amifampridine phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARGX-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKT-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bortezomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CFZ-533 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVMG-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GL-2045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KA-1463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methotrexate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit C1q for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-1654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
regenemab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPI-78M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Complement Factor D for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myasthenia Gravis - Dormant Projects
Myasthenia Gravis - Discontinued Products
Myasthenia Gravis - Product Development Milestones
Featured News & Press Releases
Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress
Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
Feb 08, 2016: Catalyst Pharmaceuticals Announces Initiation of Investigator-Sponsored Study of Firdapse in Patients With MuSK-Antibody Positive Myasthenia Gravis
Jan 26, 2016: Toleranzia takes an important step towards patent granting in Europe
Dec 09, 2015: Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis
May 29, 2015: Double recognition of Toleranzia
Feb 26, 2015: Toleranzias Receives Orphan Drug Designation For Myasthenia Gravis
Dec 10, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis
Aug 01, 2014: European Commission Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
Jun 17, 2014: FDA Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis
Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis
Apr 24, 2014: Toleranzia supported by VINNOVA
Apr 24, 2013: arGEN-X Advances ARGX-113 Into Preclinical Development For Autoimmune Disorders
Sep 14, 2011: Phase II Study of Eculizumab In Patients With Severe And Refractory Generalized Myasthenia Gravis Presented At MGFA Annual Meeting
Aug 06, 2009: European Commission And U.S. FDA Grant Alexion's Soliris (eculizumab) Orphan Drug Designation For The Treatment Of Atypical Hemolytic Uremic Syndrome (aHUS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Myasthenia Gravis, H2 2016
Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Myasthenia Gravis - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals, Inc., H2 2016
Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc., H2 2016
Myasthenia Gravis - Pipeline by arGEN-X BV, H2 2016
Myasthenia Gravis - Pipeline by Biokine Therapeutics Ltd., H2 2016
Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc., H2 2016
Myasthenia Gravis - Pipeline by CuraVac, Inc., H2 2016
Myasthenia Gravis - Pipeline by GlaxoSmithKline Plc, H2 2016
Myasthenia Gravis - Pipeline by Grifols, S.A., H2 2016
Myasthenia Gravis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
Myasthenia Gravis - Pipeline by Karus Therapeutics Limited, H2 2016
Myasthenia Gravis - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Myasthenia Gravis - Pipeline by Neurotune AG, H2 2016
Myasthenia Gravis - Pipeline by Novartis AG, H2 2016
Myasthenia Gravis - Pipeline by Pfizer Inc., H2 2016
Myasthenia Gravis - Pipeline by ReceptoPharm, Inc., H2 2016
Myasthenia Gravis - Pipeline by Regenesance BV, H2 2016
Myasthenia Gravis - Pipeline by Shire Plc, H2 2016
Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Myasthenia Gravis - Dormant Projects, H2 2016
Myasthenia Gravis - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Myasthenia Gravis, H2 2016
Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Myasthenia Gravis Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 76 pages

Ask Your Question

Myasthenia Gravis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: